Antibodies against aquaporin-4 in neuromyelitis optica: Distinction between recurrent and monophasic patients
The detection of antibodies against aquaporin-4 (AQP4) has improved the diagnosis of neuromyelitis optica (NMO). We evaluated a recently established cell-based anti-AQP4 assay in 273 patients with inflammatory CNS demyelination. The assay had a specificity of 99% and a sensitivity of 56% to detect all NMO patients and of 74% to detect the recurrent NMO patients, similar to the initial studies reported. AQP4 antibodies were absent in monophasic NMO patients, while samples in recurrent cases remained positive during follow-up. We conclude that the pathogenesis of monophasic NMO may be different from that of relapsing NMO.
|Keywords||Aquaporin-4, assays, multiple sclerosis, neuromyelitis optica|
|Persistent URL||dx.doi.org/10.1177/1352458511412995, hdl.handle.net/1765/34274|
|Journal||Multiple Sclerosis: clinical and laboratory research|
Ketelslegers, I.A, Modderman, P.W, Vennegoor, A, Killestein, J, Hamann, D, & Hintzen, R.Q. (2011). Antibodies against aquaporin-4 in neuromyelitis optica: Distinction between recurrent and monophasic patients. Multiple Sclerosis: clinical and laboratory research, 17(12), 1527–1530. doi:10.1177/1352458511412995